At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 703 enrolled
Drug / intervention
ABT-493/ABT-530drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1)
In Brief
A Phase 3 clinical trial evaluating ABT-493/ABT-530 for Chronic Hepatitis C and 2 related conditions. Completed, enrolled 703 participants.
Detailed Summary
This study seeks to evaluate the efficacy and safety of ABT-493/ABT-530 in participants with Genotype 1 hepatitis C virus infection without cirrhosis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C, Hepatitis C Virus, HCV
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartOct 2015
First PostedNov 2015
Primary CompletionJan 2017
TodayJul 2026
First PostedNov 13, 2015
Enrollment StartOct 1, 2015
Primary CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.6 years ago
Interventions
ABT-493/ABT-530drug
Tablet; ABT-493 coformulated with ABT-530